Taken together, these findings demonstrate that: 1) the pharmacological profile and molecular composition of SOCE in BC-ECFCs is similar to that described in N-ECFCs; and 2) the attenuation of VEGF-induced Ca2+ oscillations is unlikely to involve the recruitment of an alternative SOC pathway in tumor-associated cells. This evidence concerns the gene VEGFA and breast cancer.